Alperovich Anna, Younes Anas
From the Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Cancer J. 2016 Jan-Feb;22(1):23-6. doi: 10.1097/PPO.0000000000000168.
The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma (HL). CD30 is rarely expressed by normal cells and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates. Brentuximab vedotin is the first antibody-drug conjugate to be approved by regulatory agencies for the treatment of patients with relapsed HL, with a single-agent response rate of 75%. In this review article, we discuss the current and ongoing development of brentuximab vedotin in patients with relapsed and newly diagnosed HL.
CD30受体的表达是霍奇金淋巴瘤（HL）恶性里德-斯腾伯格细胞的决定性特征之一。正常细胞很少表达CD30，且其会迅速内化，这使其成为单克隆抗体和抗体药物偶联物的理想治疗靶点。维布妥昔单抗是首个获监管机构批准用于治疗复发HL患者的抗体药物偶联物，单药有效率为75%。在这篇综述文章中，我们讨论了维布妥昔单抗在复发和新诊断HL患者中的当前及正在进行的研发情况。
